10-K: SINTX Technologies 10-K Filing: Focus on Advanced Ceramics and Anti-Takeover Measures

Sentiment:

Annual Report 27 March 2024 5:10 PM

📋All filings for Sintx Technologies, INC

SINTX Technologies' 10-K filing details its business in advanced ceramics, including biomedical, technical, and antipathogenic applications, while also outlining measures to prevent hostile takeovers.

Delay expectedA furnace used for SINTX Armor manufacturing operations overheated and is no longer functional, delaying production.

Capital raiseThe company completed a public offering in February 2024, raising approximately $3.7 million in net proceeds.The company may sell shares of common stock through an Equity Distribution Agreement with Maxim Group LLC.The company will require substantial future capital in order to continue to continue operating its business.

Worse than expectedThe company has incurred net losses since its inception and anticipates that it will continue to incur substantial net losses for the foreseeable future.The company has limited committed sources of capital and limited liquidity.The company's cash and cash equivalents are only expected to fund operations through the second quarter of 2024.

Summary

SINTX Technologies is an advanced ceramics company with a focus on biomedical, technical, and antipathogenic applications.
The company manufactures silicon nitride products, including solid, porous, powder, composites, and coatings.
SINTX has a 31,000 square foot manufacturing facility in Salt Lake City, Utah, and a 15,840 square foot facility in Millersville, MD.
The company is developing ceramic armor through its subsidiary SINTX Armor, Inc.
SINTX acquired Technology Assessment and Transfer, Inc. (TA&T) in June 2022, expanding its capabilities in material processing and fabrication.
The company has incurred net losses since inception, with a net loss of $8.3 million in 2023 and $12.0 million in 2022.
SINTX's cash and cash equivalents were $3.3 million as of December 31, 2023.
The company completed a public offering in February 2024, raising approximately $3.7 million in net proceeds.
SINTX is subject to anti-takeover provisions, including a classified board of directors, blank check preferred stock authorization, and super-majority voting requirements.
The company's common stock is listed on The NASDAQ Capital Market under the symbol SINT.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While SINTX has promising technology and market opportunities, its financial losses, dependence on external funding, and competitive pressures create significant risks. The anti-takeover measures also suggest a defensive posture.

Positives

SINTX has a diverse product portfolio in advanced ceramics, including biomedical, technical, and antipathogenic applications.
The company has in-house manufacturing capabilities for silicon nitride products.
SINTX has a strong network of scientific collaborators and an experienced management team.
The company has obtained AS9100D certification and ITAR registration, facilitating entry into the aerospace and protective armor markets.
SINTX has demonstrated the antipathogenic properties of its silicon nitride, opening new market opportunities.
The company has a 10-year exclusive agreement with CTL Medical for the manufacture of spinal fusion products.
SINTX has a 10-year long-term agreement with a leading manufacturer of aerospace components and systems.
The company has received NIH grants to develop 3D printed silicon nitride/polymer implantable medical devices.

Negatives

SINTX has incurred net losses since its inception and may never achieve or sustain profitability.
The company has limited committed sources of capital and limited liquidity.
SINTX is dependent on a limited number of third-party suppliers for key raw materials.
The company faces intense competition from larger, well-established companies in the orthopedic market.
SINTX is subject to various risks related to regulatory approval of its products and other government regulations.
The company may be subject to intellectual property litigation that could consume significant resources.
SINTX may not be able to maintain its listing on the NASDAQ Capital Market.
The company is dependent on its senior management team, and the loss of any of them could harm the business.

Risks

SINTX will require additional financing, and failure to obtain it could force delays or elimination of product development programs.
Raising additional capital may dilute existing stockholders or restrict operations.
The company may not be able to compete effectively against larger, well-established companies.
SINTX depends on its customers' ability to sell the products they manufacture.
The company depends on a limited number of third-party suppliers for key raw materials.
SINTX may not be able to obtain regulatory clearance or approval for its biomedical or antipathogenic product candidates.
The company could become subject to intellectual property litigation.
SINTX may be subject to product liability claims.
The company may not be able to maintain its listing on the NASDAQ Capital Market.
Cyber security risks and the failure to maintain the integrity of company, employee or guest data could expose the company to data loss, litigation and liability.

Future Outlook

The company expects to continue to incur substantial losses for the foreseeable future as it continues to manufacture products for CTL Medical and other OEM customers and research and develop and seek regulatory approvals for its product candidates. The company expects its current cash and cash equivalents will be sufficient to fund its operations through the second quarter of 2024.

Management Comments

The Board of Directors of SINTX Technologies, Inc. believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Companys compensation philosophy.
The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. We believe the publication of such data would help sales efforts as the Company approaches new prospects.
The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.

Industry Context

SINTX operates in the competitive medical device and advanced ceramics industries, facing competition from larger, well-established companies. The company is leveraging its unique silicon nitride technology to differentiate itself in the market and expand into new applications, including aerospace and protective armor.

Comparison to Industry Standards

SINTX competes with major players in the orthopedic market such as Medtronic, DePuy Synthes, Stryker, and Zimmer Biomet, all of which have significantly greater resources and broader product offerings.
In the technical ceramics market, SINTX competes with companies like CoorsTek, Kyocera, and Saint Gobain, which are also larger and more established.
The company's silicon nitride technology is unique in the medical device space, offering potential advantages over traditional materials like PEEK, metal, and bone grafts.
SINTX's financial performance, with consistent net losses, is not uncommon for companies in the development stage, but it contrasts with the profitability of larger, established competitors.
The company's focus on in-house manufacturing provides greater control over quality and production, but also exposes it to risks associated with sole-source manufacturing.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Anti-Takeover Provisions	The company's Restated Certificate of Incorporation and Restated Bylaws contain provisions intended to enhance the likelihood of continuity and stability in the composition of the board of directors, which may have the effect of delaying, deferring or preventing a future takeover or change in control of the Company unless such takeover or change in control is approved by our board of directors.	na	These provisions could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or our best interests.
Classified Board of Directors	The board of directors is divided into three classes with staggered three-year terms.	na	This provision is likely to increase the time required for stockholders to change the composition of the board of directors.
Authorization of Blank Check Preferred Stock	The board of directors is authorized to issue, without stockholder approval, blank check preferred stock.	na	Blank check preferred stock can operate as a defensive measure known as a poison pill by diluting the stock ownership of a potential hostile acquirer.
Advance Notice Provisions	Stockholders must give timely notice of proposals and nominations in writing to the company's Secretary.	na	These provisions may prevent business from being conducted at a meeting if it is not properly brought before the meeting in accordance with the bylaw provisions.
Special Meetings of Stockholders	Special meetings of the stockholders may be called only by the board of directors.	na	This provision limits the ability of stockholders to call special meetings.
No Stockholder Action by Written Consent	Stockholders are not permitted to act by written consent.	na	Any action to be affected by stockholders must be affected at a duly called annual or special meeting of the stockholders.
Super-Majority Stockholder Vote	The affirmative vote of at least 80% of outstanding voting stock is required to amend or repeal certain provisions or to reduce the number of authorized shares.	na	This provision makes it more difficult for stockholders to amend or repeal certain provisions.

Legal Proceedings

The company is currently not a party to any material legal proceedings.

Related Party Transactions

TA&T is obligated to repay certain personal loans made by the founders of TA&T to TA&T prior to SINTXs acquisition of TA&T.

Stakeholder Impact

Shareholders face the risk of dilution from future equity offerings.
Employees may be affected by potential cost-cutting measures due to financial constraints.
Customers may be impacted by potential delays in product development or manufacturing.
Suppliers may face uncertainty due to the company's dependence on a limited number of third-party suppliers.
Creditors face the risk of non-payment due to the company's financial losses and limited liquidity.

Next Steps

The company will continue to develop new silicon nitride manufacturing technologies.
SINTX will apply its silicon nitride technology platform to new medical opportunities.
The company will develop new products with anti-pathogenic properties.
SINTX will seek strategic partners to develop and commercialize its biomedical and antipathogenic product candidates.
The company will continue to monitor its bid price and consider options to resolve the NASDAQ deficiency.

Key Dates

Date	Description
1996-12	SINTX Technologies, Inc. was formed.
2008	Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 in the US, Europe, Brazil, and Taiwan.
2010-09	SINTX acquired US Spine, Inc.
2012-02	B. Sonny Bal, M.D. joined the Board of Directors.
2014-01	Jeffrey S. White joined the Board of Directors.
2014-08	B. Sonny Bal, M.D. became Chairman of the Board of Directors.
2014-10	B. Sonny Bal, M.D. became President and Chief Executive Officer and Eric A. Stookey joined the Board of Directors.
2018-09-05	SINTX sold its spine implant business to CTL Medical.
2018-10-01	SINTX changed its corporate name from Amedica Corporation to SINTX Technologies, Inc.
2019-02	Mark Froimson, M.D. joined the Board of Directors.
2019-07	David OBrien became Executive Vice President and Chief Operating Officer.
2021-07-20	TA&T entered into a Business Loan.
2021-08-19	SINTX Armor entered into an Industrial Lease Agreement.
2022-06-30	SINTX acquired Technology Assessment and Transfer, Inc. (TA&T).
2022-10-17	SINTX completed a rights offering of units consisting of convertible preferred stock and common stock warrants.
2022-12-20	SINTX effected a 1 for 100 reverse stock split.
2023-02-10	SINTX closed on a public offering of units consisting of common stock, pre-funded warrants, and warrants.
2023-10-20	SINTX received a notice from NASDAQ regarding minimum bid price deficiency.
2024-02-02	SINTX closed on a public offering of units consisting of common stock, pre-funded warrants, and warrants.
2024-03-01	As of March 1, 2024, SINTX had 43 employees.
2024-03-11	The number of shares outstanding of the registrants common stock was 22,680,139.
2024-03-26	SINTX issued 28,400,000 common shares for approximately $1.3 million.
2024-04-17	Deadline for SINTX to regain compliance with NASDAQ minimum bid price rule.

Keywords

silicon nitride, advanced ceramics, biomedical, technical ceramics, antipathogenic, spinal fusion, ceramic armor, manufacturing, intellectual property, regulatory approval

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.